LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for lutetium lu-177 vipivotide tetraxetan and what is the scope of patent protection?
Lutetium lu-177 vipivotide tetraxetan
is the generic ingredient in one branded drug marketed by Novartis and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.Lutetium lu-177 vipivotide tetraxetan has ninety-seven patent family members in thirty-two countries.
One supplier is listed for this compound.
Summary for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
| International Patents: | 97 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 6 |
| DailyMed Link: | LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Novartis Pharmaceuticals | Phase 3 |
| Maria Sklodowska-Curie National Research Institute of Oncology | Phase 2 |
| Novartis Pharmaceuticals | Phase 2 |
See all LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN clinical trials
Pharmacology for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
| Drug Class | Radioligand Therapeutic Agent |
| Mechanism of Action | Radioligand Activity |
US Patents and Regulatory Information for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | PLUVICTO | lutetium lu-177 vipivotide tetraxetan | SOLUTION;INTRAVENOUS | 215833-001 | Mar 23, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Novartis | PLUVICTO | lutetium lu-177 vipivotide tetraxetan | SOLUTION;INTRAVENOUS | 215833-001 | Mar 23, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Novartis | PLUVICTO | lutetium lu-177 vipivotide tetraxetan | SOLUTION;INTRAVENOUS | 215833-001 | Mar 23, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Novartis | PLUVICTO | lutetium lu-177 vipivotide tetraxetan | SOLUTION;INTRAVENOUS | 215833-001 | Mar 23, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| South Korea | 20160063398 | 전립선 특이적 막 항원（ＰＳＭＡ）의 표지된 억제제, 조영제로서의 이의 용도 및 전립선암 치료용 약제 (LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER) | ⤷ Sign Up |
| Hong Kong | 1221711 | 前列腺特異性膜抗原 的標記的抑制劑，它們作為顯影劑和用於治療前列腺癌的藥劑的用途 (LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER (PSMA)) | ⤷ Sign Up |
| South Africa | 201907607 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER | ⤷ Sign Up |
| Georgia, Republic of | P20237497 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
